Guggenheim analyst Debjit Chattopadhyay raised the firm’s price target on NewAmsterdam Pharma (NAMS) to $41 from $35 and keeps a Buy rating on the shares. Compared to prior CETPi’s, obicetrapib has unique features and substantially reduced lipophilicity, which “engender favorable medicinal properties” and make the firm’s confidence into PREVAIL, which is designed to avoid the shortcomings of prior CETPi trials, “high,” the analyst tells investors.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NAMS:
- NewAmsterdam Pharma: Buy Rating Backed by Promising Obicetrapib Trials and Strong Financial Position
- NewAmsterdam Pharma files $500M mixed securities shelf
- NewAmsterdam Pharma’s 2024 Financial Results and Clinical Progress
- NewAmsterdam Pharma price target raised to $52 from $47 at Scotiabank
- Newamsterdam Pharma Faces Potential Investor Risks Due to Shareholder Influence